By leveraging high-throughput screening techniques and advanced computational tools, we sought to discover compounds that exhibit high affinity and selectivity for the mutant JAK2 kinase, crucial for driving MPN and validating them for biological efficacy. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.